Artificial tears are prescribed alone or in combination with other therapies to treat DED. Although no pharmaceutical formulas on the market aim to replace the preocular tear film, lipid substitute formulations are presently in the early clinical trial stage.
The UCM group has developed an artificial tear containing hydrophilic and lipid components that resemble the preocular tear film. Substances involved in the proliferation and differentiation of the corneal epithelium, antioxidants and osmoprotectants will be added to improve the formula. The liposomes will be dispersed in an aqueous solution of hyaluronic acid to which Vitamin C and L-carnitine or trehalose will be added.